What are Arcutis Biotherapeutics, Inc.'s profit margins?

Gross margin is 90.9% and operating margin is -12.0%, with a -13.9% net margin.

Where does Arcutis Biotherapeutics, Inc.'s income statement data come from?

Every line is extracted from Arcutis Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Arcutis Biotherapeutics, Inc. ARQT Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Total revenue	$376.07M+91.3%	$196.54M+230%	$59.61M+1,517%	$3.69M—
Total cost of revenue	$36.7M+91.8%	$19.13M+284%	$4.99M+561%	$754K—
Gross profit	$339.38M+91.3%	$177.41M+225%	$54.62M+1,763%	$2.93M—
Gross margin	90.2%0.0pp	90.3%-1.4pp	91.6%+12.1pp	79.5%—
Research and development	$77.05M+0.8%	$76.42M-30.9%	$110.58M-39.4%	$182.44M+25.3%
Selling, general and administrative	$274.55M+19.7%	$229.39M+23.9%	$185.15M+51.6%	$122.12M—
Total costs & expenses	$388.3M+19.5%	$324.94M+8.1%	$300.71M-1.5%	$305.31M+47.8%
Operating income	——	-$128.4M+46.7%	-$241.1M+20.1%	-$301.63M-46.0%
Interest expense	$12.08M-55.5%	$27.17M-8.6%	$29.71M+89.8%	$15.65M—
Interest income	——	$16.13M+28.8%	$12.52M—	——
Other income (expense), net	——	——	-$15.19M-54.5%	-$9.83M—
Income tax expense	$1.17M+81.0%	$647K-78.8%	$3.05M—	——
Net income	——	-$140.04M+46.6%	-$262.14M+15.8%	-$311.46M-50.9%
Diluted earnings per share	——	-$1.15+69.7%	-$3.79+32.4%	-$5.61-34.5%
Basic earnings per share	——	-$1.15+69.7%	-$3.79+32.4%	-$5.61-34.5%
Weighted-average shares, diluted	513.2M+7.0%	479.8M+89.2%	253.6M+18.5%	214.1M+8.8%
Weighted-average shares, basic	507.9M+5.9%	479.8M+89.2%	253.6M+18.5%	214.1M+8.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	——	-$140.05M+46.4%	-$261.05M+16.4%	-$312.29M-51.1%
Interest Income, Other	——	$16.13M+28.8%	$12.52M—	——
Net unrealized gains (losses) on securities still held	-$206K—	——	$1.19M—	——
Other income, net (Note 6)	——	——	-$796K-114%	$5.82M—
Revenue from contracts outside the scope of ASC Topic 606	$4M-86.7%	$30M-1.4%	$30.42M—	——
EBIT	——	-$128.4M+46.7%	-$241.1M+20.1%	-$301.63M-46.0%
EBITDA	——	-$125.79M-143%	-$51.76M+82.8%	-$300.69M-45.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Arcutis Biotherapeutics, Inc.'s profit margins?: Gross margin is 90.9% and operating margin is -12.0%, with a -13.9% net margin.
Where does Arcutis Biotherapeutics, Inc.'s income statement data come from?: Every line is extracted from Arcutis Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.